Maternal Hypertension, Medication Use, and Hypospadias in the National Birth Defects Prevention Study

Abstract

OBJECTIVE

To investigate whether antihypertensive classes and specific medications in early pregnancy increase the risk of severe hypospadias and to assess prior associations detected for late-treated and untreated hypertension in the National Birth Defects Prevention Study.

METHODS

Using telephone interviews from mothers of 2,131 children with severe hypospadias and 5,129 nonmalformed male control children for 1997–2009 births in a population-based case–control study, we estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) with multivariable logistic regression. We adjusted P values to account for multiple testing.

RESULTS

Forty-eight (2.3%) case and 70 (1.4%) control mothers reported early pregnancy antihypertensive treatment, 45 (2.1%) case and 31 (0.6%) control mothers reported late treatment, and 315 (14.8%) case and 394 (7.7%) control mothers reported untreated hypertension. Selective β-blockers, centrally acting agents, renin–angiotensin system-acting agents, diuretics, and specific medications, methyldopa and atenolol, were not associated with hypospadias. Nonselective β-blockers (adjusted OR 3.22, 95% CI 1.47–7.05) were associated with hypospadias; however, P values adjusted for multiple testing were not statistically significant. We confirmed prior findings for associations between hypospadias and untreated hypertension (adjusted OR 2.09, 95% CI 1.76–2.48) and late initiation of treatment (adjusted OR 3.98, 95% CI 2.41–6.55). The increased risks would translate to severe hypospadias prevalences of 11.5, 17.7, and 21.9 per 10,000 births for women with untreated hypertension, nonselective β-blocker use, and late initiation of treatment, respectively.

CONCLUSION

Our study suggests a relationship between hypospadias and the severity of hypertension.

Maternal hypertensive disorders affect up to 10% of pregnancies¹; however, data regarding specific risks of hypertension and its treatments on birth defects are limited.^2,3 Altered placental perfusion resulting from maternal hypertension^4–6 or treatment-induced iatrogenic hypotension is of particular concern.^2,7 Because placental insufficiency is a proposed mechanism in the development of hypospadias,^8–11 women with hypertension may be at greater risk of having a neonate with hypospadias.^10,12–17 Women whose hypertension becomes evident in later gestation may also be at greater risk as a result of underlying abnormal placentation that is present before abnormal fusion of the urethral folds.

Prior studies have suggested an association between hypospadias and hypertensive disorders,^{10,12,13,17,18} β-blockers,^19–21 and diuretics,²² whereas others have failed to show similar associations.^{9,15,17,21,23–28} Study limitations may explain these inconsistencies. Grouping antihypertensive treatments may obscure risks of specific classes or medications, separating the effects of maternal hypertension from those of the medication is difficult, and information on the type and severity of hypertension and on confounding resulting from to common comorbidities (eg, diabetes) is often lacking.²⁹

Previously, we used National Birth Defects Prevention Study data to examine the associations among maternal hypertension, early or late antihypertensive treatment, and severe hypospadias in the offspring.¹⁶ Compared with mothers without hypertension, we observed the highest risk in mothers initiating treatment in later pregnancy, a moderate risk in mothers with untreated hypertension, and a slight risk in mothers treated during early pregnancy. Our current study incorporated 7 additional years of data to confirm prior findings and investigate specific antihypertensive classes and medications used in early pregnancy.

MATERIALS AND METHODS

The National Birth Defects Prevention Study is the largest population-based, case–control study of birth defects in the United States.^30,31 The objective is to investigate environmental and genetic risk factors for more than 30 major structural birth defects. The study identifies cases of birth defects among liveborn neonates, fetal deaths (20 weeks of gestation or greater), and elective pregnancy terminations. Control neonates are live births without birth defects randomly selected from birth certificates or hospital discharge listings in the same population as the case neonates. Computer-assisted maternal telephone interviews are conducted within 24 months of delivery. Pregnancy dating is based on a hierarchy of information: early ultrasound scan, last menstrual period, late ultrasound scan, and neonatal examination. The National Birth Defects Prevention Study has institutional review board approvals at each site (Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, Utah) and obtains informed consent from study participants.

We studied children with severe hypospadias identified from the population-based birth defects surveillance systems of participating National Birth Defects Prevention Study sites and male control neonates with estimated dates of delivery from October 1, 1997, through December 31, 2009. Participation was 64% among case and 63% among control mothers. To confirm case diagnoses, clinical geneticists reviewed data abstracted from childrens’ medical records, including clinicians’ and nurses’ notes, consultations (urology, endocrinology, and genetic), reports (operative, pathology, and autopsy), and results of radiographic studies. Each hypospadias case was required to meet specific eligibility criteria.^16,31 Only those children with severe hypospadias (ie, subcoronal or penile, scrotal, or perineal meatal opening) diagnosed at the time of physical examination, surgery, or autopsy were included in the study. Children with coronal (“first-degree”) hypospadias, a female karyotype (46,XX), true mosaicism (46, XX/46,XY), a known or strongly suspected chromosome abnormality, a diagnosed single gene condition, certain hormonal profile or anatomical features consistent with an intersex condition, or an unconfirmed diagnosis were excluded.

Trained interviewers asked mothers about the diagnosis, timing, and treatment of “high blood pressure” for neonates with 1997–2005 estimated dates of delivery and “high blood pressure, toxemia, preeclampsia, or eclampsia” for those with 2006–2009 estimated dates of delivery. Antihypertensive medication name, start and stop dates, and frequency of use were collected for 3 calendar months before conception through the end of pregnancy; and medication use was categorized by pregnancy month. If the mother did not recall the medication name, a list of commonly prescribed anti-hypertensive medications was read to her.

We compared early pregnancy medication use (1 month preconception through pregnancy month 4) between mothers of cases and controls. This period encompassed the relevant timeframe for urethral closure (weeks 8–14 postconception),¹¹ and it permitted capture of maternal medication use before pregnancy that may have continued while the pregnancy was unrecognized. We also considered late initiation of medication (pregnancy month 5 through birth). Lastly, we considered untreated hypertension (women reporting high blood pressure during pregnancy without antihypertensive medication use).

Medications were coded using the Slone Epidemiology Center Drug Dictionary and categorized into classes: centrally acting antiadrenergic agents, β-blockers, calcium channel blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and direct vasodilators. The angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were combined into renin– angiotensin system-acting agents. We subdivided β-blockers (selective and nonselective), calcium channel blockers (dihydropyridine and nondihydropyridine), and diuretics (thiazide or thiazide-like, potassium-sparing, and loop). Mothers reporting antihypertensive medications for the treatment of other indications (eg, β-blockers for migraine headaches) were excluded from the analyses as were mothers with missing information on hypertension or antihypertensive medication use.

Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated separately for each exposure and severe hypospadias by unconditional multivariable logistic regression. We compared estimates from the original 1997–2002 data with estimates derived from the additional 7 years of data (2003–2009) to determine whether it was appropriate to combine results for the overall time period. To assess confounding, we examined categories of maternal age (younger than 20 years, 20–34, 35 or older), race or ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), education (less than high school, high school, some college, college degree), prepregnancy body mass index (calculated as weight (kg)/[height (m)]²; under-weight [less than 18.5], normal weight [18.5 to less than 25], overweight [25 to less than 30], obese [30 or higher]), parity (0, 1, 2 or more), and study site (as listed previously). We dichotomized (yes, no) fertility treatment, periconceptional folic acid use (1 month preconception through pregnancy month 1), prepregnancy and gestational diabetes, early pregnancy nausea or vomiting, early pregnancy alcohol consumption, early pregnancy smoking, multiple birth, and history of hypospadias in a first-degree relative. We stratified analyses by low birth weight (less than 2,500 g, a proxy for placental dysfunction) and pre-term birth (less than 37 weeks of gestation, a proxy for severe hypertension).^2,11 We plotted adjusted ORs with 95% CIs from stratified multivariable models, and we adjusted P values to account for multiple testing using a stepdown Bonferroni method.³²

RESULTS

Of the completed maternal interviews for 2,142 children with severe hypospadias and 5,183 non-malformed male control children, we excluded interviews with missing information on hypertension or antihypertensive medication use (eight [0.4%] in the case group, 22 [0.4%] in the control group) or use of medications with antihypertensive properties for the treatment of other indications (three [0.1%] in the case group, 32 [0.6%] in the control group); thus, our analyses included 2,131 in the case group and 5,129 in the control group. Multiple characteristics were associated with the occurrence of hypospadias (Table 1). Overall, 408 (19.1%) case and 495 (9.7%) control mothers reported hypertension during pregnancy: 48 (2.3%) case and 70 (1.4%) control mothers reported early pregnancy treatment, 45 (2.1%) case and 31 (0.6%) control mothers reported late initiation of treatment, and 315 (14.8%) case and 394 (7.7%) control mothers reported untreated hypertension.

Table 1.

Distribution of Selected Characteristics of Children With Severe Hypospadias and Nonmalformed Control Children in the National Birth Defects Prevention Study, 1997–2009

Characteristic	Children in the Case Group (n=2,131)	Children in the Control Group (n=5,129)	P
Maternal age (y)			<.001
Younger than 20	144 (6.8)	551 (10.7)
20–34	1,556 (73.0)	3,877 (75.6)
35 or older	431 (20.2)	701 (13.7)
Maternal race or ethnicity			<.001
Non-Hispanic white	1,531 (71.8)	2,942 (57.4)
Non-Hispanic black	271 (12.7)	565 (11.0)
Hispanic	182 (8.5)	1,230 (24.0)
Other	144 (6.8)	384 (7.5)
Missing	3 (0.1)	8 (0.2)
Maternal education			<.001
Less than high school	163 (7.7)	867 (16.9)
High school	416 (19.5)	1,236 (24.1)
Some college	570 (26.8)	1,341 (26.2)
College degree	937 (44.0)	1,570 (30.6)
Missing	45 (2.1)	115 (2.2)
Maternal prepregnancy BMI (kg/m2)			.387
Underweight	100 (4.7)	279 (5.4)
Normal weight	1,121 (52.6)	2,643 (51.5)
Overweight	480 (22.5)	1,118 (21.8)
Obese	386 (18.1)	858 (16.7)
Missing	44 (2.1)	231 (4.5)
Parity			<.001
0	1,144 (53.7)	2,053 (40.0)
1	622 (29.2)	1,672 (32.6)
2 or more	357 (16.8)	1,395 (27.2)
Missing	8 (0.4)	9 (0.2)
Maternal fertility treatment			<.001
Yes	214 (10.0)	204 (4.0)
No	1,917 (90.0)	4,925 (96.0)
Oral contraceptive use			.166
Yes	252 (11.9)	669 (13.1)
No	1,869 (88.1)	4,448 (86.9)
Periconceptional folic acid use			<.001
Yes	1,355 (63.6)	2,644 (51.6)
No	738 (34.6)	2,372 (46.3)
Missing	38 (1.8)	113 (2.2)
Prepregnancy diabetes			.001
Yes	28 (1.3)	29 (0.6)
No	2,102 (98.6)	5,094 (99.3)
Missing	1 (<0.1)	6 (0.1)
Gestational diabetes			.116
Yes	114 (5.4)	230 (4.5)
No	2,016 (94.6)	4,893 (95.4)
Missing	1 (<0.1)	6 (0.1)
Early pregnancy nausea or vomiting			<.001
Yes	1,319 (61.9)	3,467 (67.6)
No	802 (37.6)	1,640 (32.0)
Missing	10 (0.5)	22 (0.4)
Early pregnancy alcohol use			<.001
Yes	876 (41.1)	1,860 (36.3)
No	1,197 (56.2)	3,144 (61.3)
Missing	58 (2.7)	125 (2.4)
Early pregnancy smoking			.074
Yes	353 (16.6)	941 (18.4)
No	1,734 (81.4)	4,089 (79.7)
Missing	44 (2.1)	99 (1.9)
Multiple birth			<.001
Yes	174 (8.2)	144 (2.8)
No	1,957 (91.8)	4,958 (97.2)
Preterm birth (less than 37 wk of gestation)			<.001
Yes	561 (26.3)	484 (9.4)
No	1,568 (73.6)	4,645 (90.6)
Missing	2 (0.1)	0 (0.0)
Low birth weight (less than 2,500 g)			<.001
Yes	556 (26.1)	286 (5.6)
No	1,544 (72.5)	4,773 (93.1)
Missing	31 (1.5)	70 (1.4)
Family history (1st-degree relative)			<.001
Yes	97 (4.6)	10 (0.2)
No	2,034 (95.5)	5,119 (99.8)

BMI, body mass index.

Table 2 shows crude and adjusted estimates for the three study periods: 1997–2002, 2003–2009, and the combined 1997–2009 study period. Based on the comparability of the findings for the two individual study periods, we used the combined 1997–2009 study period in our analyses. For the 1997–2009 study period, the adjusted ORs were 1.56 (95% CI 1.05–2.33) for early pregnancy medication use, 3.98 (95% CI 2.41–6.55) for late initiation of treatment, and 2.09 (95% CI 1.76–2.48) for untreated hypertension.

Table 2.

Early Pregnancy Use of Antihypertensive Medication, Late Initiation of Antihypertensive Medication, Untreated Hypertension, and the Risk of Severe Hypospadias, the National Birth Defects Prevention Study, 1997–2002, 2003–2009, and Overall

Exposure Group* and Study Period	No. of Cases and No. of Controls	OR	95% CI	Adjusted OR†	95% CI	P	Adjusted P‡
Early use
1997–2002	19/24	2.17	1.18–3.98	1.77	0.89–3.55	.105	1.000
2003–2009	29/46	1.68	1.05–2.68	1.56	0.94–2.57	.085	1.000
Overall	48/70	1.84	1.27–2.67	1.56	1.05–2.33	.029	.620
Late initiation
1997–2002	14/13	2.94	1.38–6.29	4.49	1.85–10.91	.001	.024
2003–2009	31/18	4.58	2.55–8.22	4.23	2.26–7.94	<.001	.004
Overall	45/31	3.90	2.46–6.19	3.98	2.41–6.55	<.001	.004
Untreated hypertension
1997–2002	120/157	2.08	1.61–2.68	2.09	1.55–2.81	<.001	.004
2003–2009	195/237	2.19	1.79–2.68	2.13	1.71–2.64	<.001	.004
Overall	315/394	2.15	1.84–2.52	2.09	1.76–2.48	<.001	.004
No hypertension
1997–2002	679/1,857	Referent		Referent
2003–2009	1,045/2,777	Referent		Referent
Overall	1,723/4,634	Referent		Referent

OR, odds ratio; CI, confidence interval.

^*Women taking medications used to treat hypertension who did not report hypertension were excluded from the analysis.

^†Adjusted for site, maternal age, race and ethnicity, parity, fertility treatment, prepregnancy diabetes, gestational diabetes, and multiple birth.

^‡Adjusted using the stepdown Bonferroni method.³²

The most commonly reported medication classes used in early pregnancy were β-blockers and centrally acting antiadrenergic agents (Fig. 1). Methyldopa, labetalol, and atenolol were the most commonly reported individual medications (Table 3). Nonselective β-blockers (adjusted OR 3.22, 95% CI 1.47-7.05), including the specific medications labetalol (adjusted OR 3.02, 95% CI 1.23–7.44) and propranolol (adjusted OR 4.22, 95% CI 0.87–20.51), were associated with hypospadias, whereas selective β-blockers, centrally acting agents, calcium channel blockers, renin–angiotensin system-acting agents, and diuretics were not. Methyldopa (adjusted OR 1.48, 95% CI 0.75–2.92) and atenolol (adjusted OR 0.86, 95% CI 0.262.81) also were not associated with hypospadias. As a result of small sample sizes (less than five), we could not reliably estimate the ORs for other classes or specific medications. Figure 2 presents results stratified by low birth weight and preterm birth for early antihypertensive medication users, late initiators of medications, and untreated hypertension. For each exposure group, adjusted ORs were higher among low-birth-weight and preterm births.

Fig. 1.

Proportion of mothers reporting specific classes of antihypertensive medications among those reporting early pregnancy use.

Van Zutphen. Maternal Hypertension and Hypospadias. Obstet Gynecol 2014.

Table 3.

Early Pregnancy Use of Specific Antihypertensive Medication Classes and Drugs and the Risk of Severe Hypospadias, the National Birth Defects Prevention Study, 1997–2009

Exposure Group*	No. of Cases and No. of Controls	OR	95% CI	Adjusted OR†	95% CI	P	Adjusted P‡
Centrally acting antiadrenergic	17/29	1.58	0.86-2.88	1.42	0.74–2.71	.294	1.000
Methyldopa	15/27	1.49	0.79–2.82	1.48	0.75–2.92	.254	1.000
Clonidine	2/2	NE	NE	NE	NE
Beta-blocker	24/25	2.58	1.47–4.53	2.02	1.11–3.69	.022	.506
Selective	10/13	2.07	0.91–4.73	1.39	0.57–3.42	.470	1.000
Acebutolol	1/0	NE	NE	NE	NE
Atenolol	5/10	1.35	0.46–3.94	0.86	0.26–2.81	.802	1.000
Bisoprolol	1/0	NE	NE	NE	NE
Metoprolol	3/3	2.69	0.54–13.34	1.82	0.33–10.07	.493	1.000
Nonselective	16/12	3.59	1.69–7.60	3.22	1.47–7.05	.004	.091
Labetalol	12/9	3.59	1.51–8.53	3.02	1.23–7.44	.016	.384
Carvedilol	1/0	NE	NE	NE	NE
Nadolol	1/0	NE	NE	NE	NE
Propranolol	4/3	3.59	0.80–16.04	4.22	0.87–20.51	.075	1.000
Calcium channel blocker	4/7	1.54	0.45–5.26	1.07	0.28–4.05	.922	1.000
Dihydropyridine	4/6	1.79	0.51–6.36	1.24	0.31–4.95	.757	1.000
Amlodipine	2/4	NE	NE	NE	NE
Nifedipine	2/1	NE	NE	NE	NE
Nisoldipine	0/1	NE	NE	NE	NE
Nondihydropyridine	0/1	NE	NE	NE	NE
Verapamil	0/1	NE	NE	NE	NE
Renin–angiotensin system-acting	5/10	1.35	0.46–3.94	0.89	0.29–2.76	.843	1.000
ACE inhibitor	3/9	0.90	0.24–3.32	0.59	0.15–2.31	.444	1.000
Benazapril	1/2	NE	NE	NE	NE
Enalapril	1/0	NE	NE	NE	NE
Fosinopril	0/1	NE	NE	NE	NE
Lisinopril	0/4	NE	NE	NE	NE
Quinapril	1/0	NE	NE	NE	NE
Trandolapril	0/1	NE	NE	NE	NE
Angiotensin receptor blocker	2/1	NE	NE	NE	NE
Losartan	1/0	NE	NE	NE	NE
Olmesartan	1/0	NE	NE	NE	NE
Valsartan	0/1	NE	NE	NE	NE
Diuretic	5/11	1.22	0.42–3.52	1.09	0.35–3.39	.885	1.000
Thiazide or thiazide-like	3/8	1.01	0.273.81	0.90	0.223.72	.882	1.000
Hydrochlorothiazide	3/7	1.15	0.30–4.46	0.99	0.23–4.22	.985	1.000
Chlorthalidone	0/1	NE	NE	NE	NE
Potassium-sparing (triamterene)	0/1	NE	NE	NE	NE
Loop (furosemide)	0/1	NE	NE	NE	NE
Vasodilator (hydralazine)	0/4	NE	NE	NE	NE

OR, odds ratio; CI, confidence interval; NE, not estimable; ACE, angiotensin-converting enzyme.

^*Women taking medications used to treat hypertension who did not report hypertension were excluded from the analysis.

^†Adjusted for site, maternal age, race and ethnicity, parity, fertility treatment, prepregnancy diabetes, gestational diabetes, and multiple birth.

^‡Adjusted using the stepdown Bonferroni method.³²

Fig. 2.

Associations between early pregnancy antihypertensive medication use, late initiation of antihypertensive medication, untreated hypertension, and hypospadias stratified by low birth weight and preterm birth.

*Women taking medications used to treat hypertension, who did not report hypertension, were excluded from the analysis.

†Adjusted for site, maternal age, race/ethnicity, parity, fertility treatment, pre-pregnancy diabetes, gestational diabetes, and multiple births.

‡Adjusted using the step-down Bonferroni method.³² OR, odds ratio; CI, confidence interval.

Van Zutphen. Maternal Hypertension and Hypospadias. Obstet Gynecol 2014.

Multiple testing adjustment for the associations presented in Table 2, Table 3, and Figure 2 revealed that the P values for associations between hypospadias and early antihypertensive medication use (Table 2), β-blocker, nonselective β-blocker, and labetalol use (Table 3) for the overall study period were no longer statistically significant at α=0.05. In Figure 2, P values for the associations between hypospadias and early medication use among non-Hispanic black mothers and late initiation among non-Hispanic white mothers, term births, and low-birth-weight births were no longer statistically significant.

DISCUSSION

We confirmed our earlier findings of associations between hypospadias and both untreated hypertension and late initiation of antihypertensive medications.¹⁶ Our findings agree with several studies that have suggested a relationship between preeclampsia or gestational hypertension and hypospadias^{10,12,13,17,18}; however, others have not demonstrated this association.^9,15,23,24 Inadequate spiral artery invasion of the placenta may affect uteroplacental perfusion early in gestation in women with gestational hypertension or preeclampsia,^4–6 and placental insufficiency might affect fetal somatic and urethral development.^8–11,17 Brouwers et al¹⁷ observed that low birth weight and preeclampsia showed the strongest associations with the proximal type of hypospadias (which corresponds to our severe hypospadias cases). Notably, we found the strongest associations for all categories of exposure among neonates with low birth weight (a proxy for placental dysfunction) and preterm births (a proxy of severe hypertension).^2,11

Early pregnancy use of centrally acting antiadrenergic, selective β-locker, renin–angiotensin system-acting, and diuretic medications were not associated with hypospadias in our study. However, we detected an association for nonselective β-blockers: an appreciable and stable association for labetalol and a less stable elevated risk for propranolol. These results are in contrast with a study that found no associations between β-blockers and genital or urinary anomalies,²⁶ but agree with a study that reported a greater than expected number of hypospadias cases in pregnancies exposed to propranolol.²⁰ The association with labetalol might be confounded by the severity of the hypertension because labetalol is used for the urgent control of severe hypertension in pregnancy.^2,3 Alternatively, the association might reflect a treatment-induced reduction in placental blood flow. Treatment-induced decreases in mean arterial pressure were associated with inadequate fetal growth in a meta-analysis of randomized controlled trials of pregnancy hypertension.⁷ Assuming these decreases are associated with reduced placental blood flow, maternal antihypertensive medication use during the time of urethral development might cause hypospadias. Notably, an in vitro study of human umbilical artery resistance showed that labetalol, hydralazine, and nifedipine significantly affected fetoplacental circulation, whereas α-methyldopa did not.³³ These findings are consistent with both Doppler ultrasound studies, which showed that α-methyldopa does not affect uteroplacental or fetal hemodynamics^33,34 and a sheep model of maternal hypertension in which labetalol and pindolol (another nonselective β-blocker) compromised uteroplacental perfusion.³⁵ Beta-blockers also may affect urethral development by interfering with Leydig cell activity in the testis. Leydig cells begin production of testosterone by week 8 and influence sexual differentiation.³⁶ Because β-2-type receptors play a role in Leydig cell activity, nonselective β-blockers may interfere with urethral development.³⁷ Furthermore, β-blockers induced significant decreases in testosterone in male rats.³⁸

The strength of our study is that we used data from the National Birth Defects Prevention Study, a large, population-based study with a standardized protocol for maternal interviews performed within 24 months of the estimated due date and strict definitions and clinical review for consistent case classification. Data on timing of medication use and maternal health and lifestyle factors permitted evaluation of specific medications during the window of urethral closure and evaluation of confounding and effect modification. Our inability to classify the type or severity of hypertension constrained our ability to evaluate confounding by indication.²⁹ Reporting inaccuracy and recall bias resulting from retrospective ascertainment of medication exposures were minimized through a questionnaire design that elicited medication use by indication.^29,39 Recall of prescription chronic hypertension medications is likely to be reasonably accurate.³⁹ Differential recall among case mothers is not likely because we observed associations for some medications and not others. Correlated lifestyle or maternal characteristics also could bias our findings. Lastly, sample sizes for a number of medications were small, leading to imprecise estimates.

This study contributes new data on the risks and relative safety of maternal hypertension and its treatments during pregnancy. The findings of associations between nonselective β-blockers and hypospadias require confirmation. Severe hypospadias affects approximately 5.5 per 10,000 births⁴⁰; thus, the increased risks for women with untreated hypertension, nonselective β-blocker use, or late initiation of treatment would translate to severe hypospadias prevalences of 11.5, 17.7, and 21.9 per 10,000 births, respectively, a modest increase relative to the baseline risk of 200–300 per 10,000 for any major birth defect. For severe hypertension, continuation of treatment during pregnancy is necessary for maternal and fetal health; however, there is no consensus on the necessity of medication use for mild to moderate hypertension during pregnancy.^2,3 Our findings might be considered in a risk–benefit assessment for treatment choices in these women.